Diadema Partners’s Nektar Therapeutics NKTR Stock Holding History

Diadema Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-47,474	Closed	-$85.9K	–	150
2025 Q2	$85.9K	Buy	47,474 +2,261	+5%	+$25.4K	0.03%	91
2025 Q1	$461K	Buy	+45,213	New	+$591K	0.12%	79

Other funds holding NKTR

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diadema Partners's NKTR Position: Q4 2025 in Review

Diadema Partners sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 75,000 shares — an estimated $4.27M sold.

Diadema Partners first reported a position in NKTR in Q4 2024 and held it in 2 quarters. The position peaked at $4.27M in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

Diadema Partners reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 75,000 Nektar Therapeutics shares in Q4 2025, an estimated $4.27M.
Diadema Partners first reported a position in Nektar Therapeutics in Q4 2024 and held it in 2 quarters.
Diadema Partners's Nektar Therapeutics position peaked at $4.27M in Q3 2025.
180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.